152 related articles for article (PubMed ID: 22526138)
1. Treatment of anorexia nervosa with TNF-α down-regulating agents.
Bou Khalil R; de Muylder O; Hebborn FL
Eat Weight Disord; 2011 Dec; 16(4):e300. PubMed ID: 22526138
[No Abstract] [Full Text] [Related]
2. Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis.
Barber J; Sheeran T; Mulherin D
Ann Rheum Dis; 2003 May; 62(5):490-1. PubMed ID: 12695170
[No Abstract] [Full Text] [Related]
3. When should we use TNF antagonists in children with rheumatic disease?
Quartier P
Joint Bone Spine; 2007 Jan; 74(1):1-3. PubMed ID: 17174585
[No Abstract] [Full Text] [Related]
4. Anti-tumor necrosis factor therapy is tolerated in an individual with homozygous complement C2 deficiency.
Momeni M; Mehta AP; Katz JD
J Clin Rheumatol; 2005 Jun; 11(3):180-2. PubMed ID: 16357744
[No Abstract] [Full Text] [Related]
5. Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab.
Nowak B; Jeka S; Wiland P; Szechiński J
Joint Bone Spine; 2009 Mar; 76(2):217-9. PubMed ID: 19196533
[No Abstract] [Full Text] [Related]
6. Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab.
Takezaki S; Okura Y; Ichikawa M; Suzuki D; Ohshima J; Kaneda M; Cho Y; Yamada M; Kawamura N; Iguchi A; Kobayashi I; Ariga T
Mod Rheumatol; 2012 Aug; 22(4):621-4. PubMed ID: 22072226
[TBL] [Abstract][Full Text] [Related]
7. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
8. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
Shenoi S; Wallace CA
Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
[TBL] [Abstract][Full Text] [Related]
10. Atlanto-axial subluxation in a patient with polyarticular juvenile idiopathic arthritis: clinical and radiological response to infliximab.
Cannioto Z; Taddio A; Lepore L; Zennaro F
Clin Exp Rheumatol; 2008; 26(4):704-5. PubMed ID: 18799110
[No Abstract] [Full Text] [Related]
11. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis.
Norambuena R X; Mallol J; Ríos M G; Quevedo R F; Quezada L A
Allergol Immunopathol (Madr); 2007; 35(2):52-6. PubMed ID: 17428400
[TBL] [Abstract][Full Text] [Related]
13. Juvenile idiopathic arthritis: current and future treatment options.
Martini G; Zulian F
Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
[TBL] [Abstract][Full Text] [Related]
14. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children.
Billiau AD; Cornillie F; Wouters C
J Rheumatol; 2002 May; 29(5):1111-4. PubMed ID: 12022340
[No Abstract] [Full Text] [Related]
16. Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?
Prince FH; Solomon DH
J Rheumatol; 2013 Oct; 40(10):1643-5. PubMed ID: 24085753
[No Abstract] [Full Text] [Related]
17. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis.
Mangge H; Heinzl B; Grubbauer HM; El-Shabrawi Y; Schauenstein K
Rheumatol Int; 2003 Sep; 23(5):258-61. PubMed ID: 12687288
[TBL] [Abstract][Full Text] [Related]
19. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
20. [Biological therapy treatment of juvenile idiopathic arthritis].
Herlin T
Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
